Written edition
Neuralink loses the brain-chip first-mover crown—China already implanted one
A cascade of regulatory and market shifts across six sectors signals that the frontier is no longer waiting for Western gatekeepers.
Brain chips, defense innovation, and satellite connectivity are all accelerating outside traditional approval lanes, while even legacy industries—mobility, semiconductors—are confronting fundamental unit-economics reckoning.
China implants first commercial brain chip before Neuralink clears FDA trials
Beijing just placed a neural interface implant into a patient's brain and called it commercial, leapfrogging Neuralink's FDA-bound timeline. The pivot isn't just symbolic—China's version already qualifies for insurance coverage, which means regular patients might access it affordably before the U.S. version even launches. This collapses the assumption that approval pace determines market leadership, and signals that the brain-computer interface race is now two-track, with capital and regulatory paths diverging sharply.
